In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
10 authors.
Corinna A KulickeDivision of Pulmonary, Allergy, and Critical Care Medicine, Oregon Health & Science University, Portland, OR 97239, USA.ORCID 0000-0002-4217-3095 Chance LemonDivision of Pulmonary, Allergy, and Critical Care Medicine, Oregon Health & Science University, Portland, OR 97239, USA.ORCID 0009-0007-3958-7303 Jason R KrawicDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.ORCID 0000-0003-0103-0212 Luisa Maria Nieto RamirezDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA.ORCID 0000-0003-1566-5876 Se-Jin KimDivision of Pulmonary, Allergy, and Critical Care Medicine, Oregon Health & Science University, Portland, OR 97239, USA.
Gitanjali NarayananDepartment of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA.
Fikadu G TafesseDepartment of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR 97239, USA.ORCID 0000-0002-8575-4164 William H HildebrandDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Karen M DobosDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA.ORCID 0000-0001-7115-8524 David M LewinsohnDivision of Pulmonary, Allergy, and Critical Care Medicine, Oregon Health & Science University, Portland, OR 97239, USA.ORCID 0000-0001-9906-9494 Funding
Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4MResearch Resources and Workforce Development for the Rocky Mountain Regional Biocontainment Laboratory at Colorado State UniversityUC7AI180308 · NIAID · COLORADO STATE UNIVERSITY · PI Karen Marie Dobos · 2023 to 2026
$13.5MT cell recognition of the MR1 presented microbial metabolomeR01AI147954 · NIAID · UNIVERSITY OF CHICAGO · PI ADAMS, ERIN JUNE, HILDEBRAND, WILLIAM · 2019 to 2023
$7.3MRegional Biocontainment Laboratory (RBL) Upgrade for Colorado State University (CSU)G20AI167348 · NIAID · COLORADO STATE UNIVERSITY · PI DOBOS, KAREN MARIE · 2021 to 2022
$6.5MMultidisciplinary Research Training in Pulmonary MedicineT32HL083808 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI LEWINSOHN, DAVID M., SLATORE, CHRISTOPHER G. · 2008 to 2025
$5.3MLung Resident, MR1-Restricted T Cells: Association with Differential Outcomes Following Exposure to M. TuberculosisR01AI134790 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI LEWINSOHN, DAVID M., WALZL, GERHARD · 2018 to 2022
$3.3MDetermining the role of sphingolipids in Mycobacterium tuberculosis infectionR01AI141549 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI TAFESSE, FIKADU G. · 2020 to 2025
$2.4MHigh Performance Computing and Machine Learning Infrastructure for Oregon Life SciencesS10OD034224 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLROTT, KYLE · 2023 to 2023
$2.0MBLRD VA I01 BX000533NCATS NIH HHS UL1 TR002369NHLBI NIH HHS T32 HL083808NIAID NIH HHS G20 AI167348NIAID NIH HHS R01 AI134790NIAID NIH HHS R01 AI141549NIAID NIH HHS R01 AI147954NIAID NIH HHS UC7 AI180308NIH HHS S10 OD034224
6 · The paper itselfAbstract
The antigen presenting molecule MHC class I-related protein 1 (MR1) binds small molecule metabolites derived from microbial riboflavin biosynthetic pathways and presents them at the cell surface for surveillance by MR1-restricted mucosal-associated invariant T cells (MAIT cells). MR1 ligands can originate in the extracellular space or in endosomal compartments that contain microbial pathogens. Distinct, complementary antigen processing and presentation pathways enable MR1 to survey diverse intracellular locations and present both exogenous and intracellular antigens. Here, we generated a panel of BEAS-2B MR1 KO cells reconstituted with MR1 proteins mutated at amino acids 9 - 16. The mutated MR1 molecules differentially translocated to the cell surface in response to 6-formylpterin and differed in their ability to present mycobacterial antigens to MAIT cell clones. While they barely presented
Indexed as
antigen presentationcellular immune responseMAIT cellsMR1-restricted T cellsmucosal immunologyT-cell
Identifiers
PMID40475583
PMCPMC12139987
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390